GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Size:

The global GLP-1 receptor agonist market size reached US$ 24.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.82% during 2024-2032. The market is undergoing notable growth, principally boosted by escalating incidents of type 2 diabetes across the globe and heightening need for effective glucose-lowering drugs. Moreover, proliferating product applications in cardiovascular diseases and weight management, coupled with innovations in drug delivery techniques, are further boosting market expansion.

GLP-1 Receptor Agonist Market Analysis:

• Major Market Drivers: The market is chiefly driven by the amplifying incidents of type 2 diabetes and the soaring awareness about the effective control of this disorder. The requirement for GLP-1 receptor agonist (RAs) is further spurred by their validated efficacy in controlling the levels of blood glucose and assisting weight loss. Moreover, the widening range of applications, particularly in treating cardiovascular diseases, is contributing to the market's growth. Additionally, the development of innovative drug delivery methods, such as oral administration, is enhancing patient adherence, accelerating the drug's adoption. Furthermore, the rising global diagnosis and awareness of Type 2 diabetes mellitus are expected to boost market growth, as healthcare systems increasingly prioritize effective disease management solutions. 
• Key Market Trends: Key market trends include heightening need for effective pharmaceutical drugs for weight control and management, beyond their conventional use in diabetes treatment. Furthermore, combination therapies are gaining momentum in the market dynamics because of their superior effectiveness in treating certain disorders. In addition, advancements in drug delivery techniques, such as oral formulations of once-a-week injections, are enhancing patient outcomes. The market is also experiencing growth in cardiovascular disease treatment, mainly driven by clinical validation exhibiting the cardiovascular advantages of GLP-1 RAs.
• Geographical Trends: North America dominates the global GLP-1 receptor agonist market, driven largely by the rising prevalence of diabetes and a strong healthcare infrastructure. The United States plays a pivotal role in this expansion, with widespread adoption of GLP-1 RAs in Type 2 diabetes management. The region's focus on advanced pharmaceutical treatments, including innovative drug delivery methods, further increases GLP-1 receptor agonist market value. Additionally, North America's well-established regulatory framework facilitates the approval and adoption of new therapies, solidifying its position as the leading regional market in this evolving global sector.
• Competitive Landscape: Some of the major market players in the GLP-1 receptor agonist industry include Amgen Inc., Eli Lilly and Company, Hanmi Pharm Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Novo Nordisk A/S, Paige Biomedicine (Suzhou) Co., Ltd., Sanofi S.A., among many others.
• Challenges and Opportunities: The market witness numerous challenges, including the rising demand for enhanced patient compliance to injectable solutions and elevated treatment costs. Nevertheless, notable opportunities exist as well, especially in proliferating the utilization of GLP-1 RAs beyond diabetes treatment, and into application segments such as cardiovascular associated disorders and weight management. The formulation of patient-friendly drug delivery methods, such as oral administration, offers a pivotal growth opportunity. Moreover, increasing diagnosis and awareness of Type 2 diabetes are expected to provide the opportunity of expanding the market significantly.
   

GLP-1 Receptor Agonist Market Trends:

Increasing Prevalence of Type 2 Diabetes

The global market for GLP-1 receptor agonist is undergoing significant expansion, predominantly because of the escalating prevalence of type 2 diabetes. As the population of diabetic patients is continuously expanding around the world, the demand for effective glucose-lowering treatments is magnifying significantly. According to a study published in April 2024, around 530 million adults around the world are affected by diabetes, with almost 98% of patients diagnosed with Type 2 diabetes. GLP-1 RAs have established themselves as an ideal therapy solution particularly due to their certified effectiveness in regulating the levels of blood sugar and controlling overweight issues. Moreover, this accelerated utilization of the drug is further fueled by healthcare providers striving to improve treatment results, consequently bolstering the significant development of the GLP-1 receptor agonist market. In addition, the heightening emphasis on early intervention and thorough diabetes management is also intensifying this trend.

Increasing Product Utilization for Weight Management

According to the GLP-1 receptor agonist market report, a growing trend is observed in the product’s application for weight management, beyond its conventional utilization in treating Type 2 diabetes. Globally, obesity rates are accelerating significantly, compelling the healthcare professionals to prescribe these drugs mainly for their certified efficacy in facilitating weight loss, particularly in diabetic patients. According to the World Obesity Federation, in 2024, more than 1 billion people around the world are obese, including approximately 159 million adolescents and children, and 880 million adults. This data suggests that around 3 billion people are living with either obesity or overweight. Moreover, pharmaceutical firms are actively profiting from this trend by executing clinical trials and striving for regulatory validation for weight management indications, further broadening the market’s prospects. In addition, this inclination towards weight management drugs is appealing a broader patient demographic and propelling demand for GLP-1 receptor agonists (RAs) in wellness as well as healthcare industry.

Rapid Innovations in Drug Delivery Systems

The GLP-1 receptor agonist market research report suggests that innovations in drug delivery techniques is one of the crucial trends steering the global market growth. Manufacturers are currently emphasizing on formulating more patient-friendly and convenient administration systems, such as oral methods or once-weekly injections, to enhance patient experience and adherence. According to a research article published in February 2024, certain GLP-1 RAs drugs like Semaglutide or Exenatide leverage subcutaneous delivery system to attain peak concentrations more quickly and ensure rapid absorption. In addition, an innovative oral delivery technique has been formulated for Semaglutide to facilitate gastrointestinal absorption, with consideration for bioavailability aspects. Such innovations are pivotal in a market where ease of use and patient suitability are increasingly becoming essential determinants in treatment selection. Resultantly, new, innovative drug delivery systems are bolstering competitive among major pharmaceutical companies and spurring the potential of market growth. 

GLP-1 Receptor Agonist Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, route of administration, application, and distribution channel.

Breakup by Product:

• Victoza
• Ozempic
• Trulicity
• Bydureon
• Saxenda
• Others
   

Trulicity accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes victoza, ozempic, trulicity, bydureon, saxenda, and others. According to the report, trulicity represented the largest segment.

As per the GLP-1 receptor agonist market overview, trulicity accounts for the largest share of the global market largely due to its reliable effectiveness, well-established and clinically verified safety credentials, and ease of once-a-week dosing. Trulicity is currently the leading drug and has procured extensive adoption among patients as well as healthcare personnels for treating Type 2 diabetes. According to industry reports, global sales of trulicity accounted for approximately USD 7.13 billion in 2023. Moreover, its ability to facilitate weight management and enhance glycemic regulation has augmented its leadership in the global market share. In addition, strong growth of sales and success of ongoing clinical trials further fortifies the dominant position of this segment.

Breakup by Route of Administration:

• Parenteral
• Oral
   

Parenteral holds the largest share of the industry

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes parenteral and oral. According to the report, parenteral accounted for the largest market share.

The GLP-1 receptor agonist market forecast indicates that parenteral administration is expected to maintain its leading position globally, largely because of its effectiveness in delivering GLP-1 RAs drugs directly into the bloodstream, ensuring rapid absorption and optimal treatment results. Moreover, this route is specially preferred for GLP-1 RAs due to the requirement for accurate dosing and uniform drug delivery, which is critical in treating chronic diseases like Type 2 diabetes. In addition, the well-established infrastructure for injectable treatments further strengthens its domination in the global market dynamics. 

Breakup by Application:

• Type 2 Diabetes Mellitus
• Obesity
• Others
   

Type 2 diabetes mellitus represents the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the application. This includes type 2 diabetes mellitus, obesity, and others. According to the report, type 2 diabetes mellitus represented the largest segment.

Type 2 diabetes mellitus represents the largest segment, majorly driven by the increasing prevalence of the disease around the world. According to the National Institutes of Health, by 2030, the number of Type 2 diabetic patients is forecasted to increase to 7,079 per 100,000 individuals. The efficiency of the drug in controlling the blood glucose levels, coupled with their added advantages of fostering weight loss and lowering the risks of cardiovascular diseases, is significantly contributing to the rising GLP-1 receptor agonist market revenue. Moreover, the heightening awareness, amplified diagnostics rates, and proliferating healthcare infrastructure further fortify the leadership of Type 2 diabetes mellitus application within the segment.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Diabetes Clinics
• Online Pharmacies
   

Hospital pharmacies exhibit a clear dominance in the market 

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, diabetes clinics, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies are the primary and most influential distribution channel, significantly driving the GLP-1 receptor agonist market growth by playing a vital role in providing specialized care for chronic conditions like Type 2 diabetes mellitus. Such pharmacies facilitate the constant availability of GLP-1 RAs, supporting patient compliance and complex treatment frameworks. In addition, the ability of these pharmacies to provide direct connectivity with healthcare personnels and personalized drug management establishes them as an ideal distributional channel for supplying these therapeutics, further strengthening their domination in the distribution network.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest GLP-1 receptor agonist market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for GLP-1 receptor agonist.

North America is the leading regional market primarily because of the rising prevalence of obesity and Type 2 diabetes in this region. According to the Center for Disease Control and Prevention, more than 38 million people, or around 1 in 10, in the United States are living with diabetes, while approximately 90%-95% of them are diagnosed with Type 2 diabetes. This contributes to a positive GLP-1 receptor agonist market outlook in the region by propelling the sales of the product for the treatment of this chronic disorder. Moreover, North America’s robust healthcare infrastructure, coupled with substantial investments in advanced therapies further facilitates in sustaining the leading position. In addition, rising awareness among patients and healthcare providers about the perks of GLP-1 RAs, along with beneficial repayment policies, also accelerates the regional market growth. North America’s expansive pharmaceutical sector also plays a crucial role in spurring this dominance.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the GLP-1 receptor agonist industry include Amgen Inc., Eli Lilly and Company, Hanmi Pharm Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Novo Nordisk A/S, Paige Biomedicine (Suzhou) Co., Ltd., and Sanofi S.A.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The global GLP-1 receptor agonist market is extremely competitive, with major companies participating in strategic collaborations to expand their research or production capacities. For instance, in August 2024, Eli Lilly and Company, one of the leading producers of Trulicity, and Purdue University reinforced their well-established strategic research collaboration by launching a research alliance center named LPRC, which will focus on optimizing all stages of pharmaceutical research, from discovery to delivery. Such companies utilize their robust product portfolios to sustain their domination in the global market and accelerate GLP-1 receptor agonist demand. Moreover, the market is also experiencing heavy competition from emerging biopharmaceutical companies that are actively formulating innovative delivery techniques, further fueling the competitive landscape, and fostering unceasing advancements and market growth.

GLP-1 Receptor Agonist Market News:

• In August 2024, Novo Nordisk, a pharmaceutical company well known for its GLP-1 drug Ozempic, announced the development of a new raw ingredients plant in Denmark, with an investment of USD 220 million. The company anticipates completing the plant construction by 2027. This plant will focus on processing raw materials for manufacturing drugs for chronic diseases, including diabetes.
• In December 2023, Eli Lilly and Company, one of the major GLP-1 receptor agonist companies, announced the availability of Zepbound (tirzepatide) injection, a GLP-1 drug, in the U.S. pharmacies for the treatment of Type 2 diabetes mellitus, hypertension, and cardiovascular diseases.

GLP-1 Receptor Agonist Market Report Scope:

Key Questions Answered in This Report:

• How has the global GLP-1 receptor agonist market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global GLP-1 receptor agonist market?
• What is the impact of each driver, restraint, and opportunity on the global GLP-1 receptor agonist market?
• What are the key regional markets?
• Which countries represent the most attractive GLP-1 receptor agonist market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the GLP-1 receptor agonist market?
• What is the breakup of the market based on the route of administration?
• Which is the most attractive route of administration in the GLP-1 receptor agonist market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the GLP-1 receptor agonist market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the GLP-1 receptor agonist market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global GLP-1 receptor agonist market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the GLP-1 receptor agonist market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global GLP-1 receptor agonist market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the GLP-1 receptor agonist industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.